{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-005242","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.982944+00:00","generated_at":"2026-06-26T12:19:15.521664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Finch Therapeutics Q4 2021 net loss $19.1M; PRISM4 trial on hold, CFO retiring","bullets":["Net loss of $19.1M in Q4 2021 ($13.1M in Q4 2020); full year loss $58.2M ($39.3M in 2020).","Cash and equivalents $133.5M at Dec 31, 2021; expected to fund operations into mid-2023.","PRISM4 Phase 3 trial of CP101 in recurrent C. difficile remains on clinical hold; at least one quarter delay.","Paused development of CP101 for chronic HBV to focus on CDI and autism programs.","CFO Greg Perry to retire April 30, 2022; COO Marc Blaustein to serve as principal financial officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-005242","json":"https://secwatch.observer/filing/0000950170-22-005242.json","markdown":"https://secwatch.observer/filing/0000950170-22-005242.md","text":"https://secwatch.observer/filing/0000950170-22-005242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022005242/0000950170-22-005242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022005242/fnch-20220331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T12:19:15.521664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}